Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OXIRI
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
OXIRI is a chemotherapy regimen comprising oxaliplatin, capecitabine (Xeloda), and irinotecan. It is being investigated for the treatment of advanced and/or metastatic pancreatic adenocarcinoma and metastatic pancreatic cancer. The regimen is designed to be more tolerable than FOLFIRINOX, with chronomodulated capecitabine administration and UGT1A1 genotype-guided dosing of irinotecan. It has shown preliminary evidence of efficacy and immunomodulatory effects.
- Other names
- Low Dose OXIRImetronomic capecitabine + metronomic oxaliplatin + irinotecan
02
Targets
DNATOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on OXIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OXIRI.